Products
Resources
Company

Virtual lab

Keep in contact

Products +

Resources +

Company +

Virtual lab

Keep in contact

Reserved Area

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Archiv

Your next step starts here. Fill out the form and talk to us

Let's talk

Subscribe to Our Newsletter

Products

Solid tumor
Blood cancer
Pharmacogenetics

Instruments

Labcycler

Resources

Knowledge Hub
Publications
Reserved area

Company

About us
Virtual lab
Careers
Press hub
Scientific board
Contacts

Corporate

Group
Code of ethics
Certifications
Partnership

Legal

Whistleblowing
Cookie policy
Privacy policy

Follow us on

LinkedIn
Youtube

Reg. Office: Via Ignazio Silone 1/B, 60035 Jesi (AN), IT
VAT No.: 02483840423 – SDI Code: M5UXCR1 – Tel.: +39 0731 213243

The registered names and trademarks indicated in this website have to be considered protected by law, even when not explicitly stated.

Credits

Subscribe to Our Newsletter

First name

Last name

Company / Istitution

Country

I confirm that I have read the information on the personal data management.

I agree to the processing of my personal data according to the above mentioned information

You are leaving this research use-only area

You are about to access content intended for a different region. Information, regulatory status, and product availability may vary by location.

Do you wish to continue?

Continue

Cancel

Select Your Region

Please select your region to access the content that is most relevant to your location and applicable regulations.

EU / Rest of World

US / Canada